Journal article
Clinical Implications of Echocardiographic Phenotypes of Patients With Diabetes Mellitus
L Ernande, E Audureau, CL Jellis, C Bergerot, C Henegar, D Sawaki, G Czibik, C Volpi, F Canoui-Poitrine, H Thibault, J Ternacle, P Moulin, TH Marwick, G Derumeaux
Journal of the American College of Cardiology | ELSEVIER SCIENCE INC | Published : 2017
Abstract
Background Type 2 diabetes mellitus (T2DM) may alter cardiac structure and function, but obesity, hypertension (HTN), or aging can induce similar abnormalities. Objectives This study sought to link cardiac phenotypes in T2DM patients with clinical profiles and outcomes using cluster analysis. Methods Baseline echocardiography and a composite endpoint (cardiovascular mortality and hospitalization) were evaluated in 842 T2DM patients from 2 prospective cohorts. A cluster analysis was performed on echocardiographic variables, and the association between clusters and clinical profiles and outcomes was assessed. Results Three clusters were identified. Cluster 1 patients had the lowest left ventri..
View full abstractGrants
Awarded by Société Francophone du Diabète
Funding Acknowledgements
This work was supported by a grant from the Societe Francophone du Diabete (formerly the Association of French Language for the Study of Diabetes Mellitus and Metabolic Diseases, grant number D20515) and a grant from the Programme Hospitalier de Recherche Clinique (PHRC 2009-A00089-48). This work was also supported by the French National Agency through the Recherche Hospital-Universitaire-Cardiac & Skeletal Muscle Alteration in Relation to Metabolic Diseases and Ageing: Role of Adipose Tissue (RHU-CARMMA) Grant ANR-15-RHUS-0003. Dr Canoui-Poitrine has epidemiologic expertise and participated on a scientific committee for an observational study in Parkinson's disease, and received honoraria from ABBVIE, France. Dr. Moulin has participated in investigator clinical trials for Sanofi, Pierre Fabre, and Merck Sharp & Dohme; has served on the advisory board of Sanofi; has spoken at symposia for Sanofi, Merck Sharp & Dohme, and Novo Nordisk; and has participated in academic congresses for Janssen, Boehringer, Amgen, and AstraZeneca. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Drs. Ernande and Audureau contributed equally to this work. Drs. Marwick and Derumeaux contributed equally to this work and are joint senior authors. Maurizio Galderisi, MD, served as Guest Editor for this paper.